FDA Approves Lilly's Ebglyss (lebrikizumab) for Atopic Dermatitis
Ebglyss, a new first-line biologic treatment for moderate-to-severe atopic dermatitis, offers significant skin clearance within four weeks and itch relief in two weeks. It provides long-lasting efficacy through monthly maintenance doses, approved by the FDA for adults and children 12 years and older who weigh at least 88 pounds (40 kg) and have inadequate response to topical therapies.
Reference News
Ebglyss, a new first-line biologic treatment for moderate-to-severe atopic dermatitis, offers significant skin clearance within four weeks and itch relief in two weeks. It provides long-lasting efficacy through monthly maintenance doses, approved by the FDA for adults and children 12 years and older who weigh at least 88 pounds (40 kg) and have inadequate response to topical therapies.